Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2002
10/30/2002EP1251858A2 Podophyllotoxin compositions
10/30/2002EP1251857A1 Pharmaceutical parenteral composition containing a bisphosphonate
10/30/2002EP1251853A1 Transdermal therapeutic system for the administration of zaleplon
10/30/2002EP1251845A1 Purifying polyoxyethylated castor oils with activated charcoal and pharmaceutical formulations thereof
10/30/2002EP1251844A2 Laxative preparation containing l-arginine
10/30/2002EP1251843A1 Compositions for delivery of a cortisol antagonist
10/30/2002EP1251841A1 Aqueous solution for treating degenerative or autoimmune diseases and as immunomodulatory agent
10/30/2002EP1251837A2 Compounds and methods for modulating cerebral amyloid angiopathy
10/30/2002EP1251832A2 Shell-and-core dosage form approaching zero-order drug release
10/30/2002EP1251831A1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor
10/30/2002EP1251829A1 Electrospun pharmaceutical compositions
10/30/2002EP1251827A2 Nasally administrable cyclic peptide compositions
10/30/2002EP1251826A1 Diclofenamide suspension gel
10/30/2002EP1251750A1 Improved pediatric formula and methods for providing nutrition and improving tolerance
10/30/2002EP1251739A2 Poly(dipeptide) as a drug carrier
10/30/2002EP1011634B1 Preparation of pharmaceutical compositions
10/30/2002EP0918509A4 Biocompatible devices with foam scaffolds
10/30/2002EP0852243B1 Polyethylene oxides having saccharide residue at one end and different functional group at another end, and process for producing the same
10/30/2002EP0828495B1 Stabilized solid dispersions of misoprostol
10/30/2002EP0812195B1 Pharmaceutical composition for piperidinoalkanol compounds
10/30/2002EP0695187B1 Inhibition, control and regression of angiogenesis with hyaluronic acid or hyaluronic acid and nsaid
10/30/2002CN1377283A Process to make a sustained release formulation
10/30/2002CN1377282A Fatty acid-anticancer conjugates and uses thereof
10/30/2002CN1377280A Diagnosis and treatment of neuroectodermal tumors
10/30/2002CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002CN1377267A Retard form containing 2-lipoic acid (derivatives)
10/30/2002CN1377266A Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion
10/30/2002CN1377264A Method for treating endometriosis or infertility, or improving fertility
10/30/2002CN1377262A Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses
10/30/2002CN1377258A Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
10/30/2002CN1377257A Hybrid matrices and hybrid matrix mixtures
10/30/2002CN1377235A Nutritional compositions which contain non-digestible polysaccharides and use thereof to reduce transport through tight junctions
10/30/2002CN1376735A Antibiotics-polymer composition
10/30/2002CN1376518A Stable lactase composition
10/30/2002CN1376516A Injection-type compound bone repairing material containing more biological factors and using animal fibrin as carrier
10/30/2002CN1376469A Slow release antibiotics preparation of bioactive substance
10/30/2002CN1376460A Fat emulsion for injection and its preparing process
10/30/2002CN1376459A Preparation method for antibiotics composition
10/29/2002US6472537 Polyamides for binding in the minor groove of double stranded DNA
10/29/2002US6472511 Stimulation of an immune response with antibodies labeled with the α-galactosyl epitope
10/29/2002US6472507 Carrier based drug delivery system
10/29/2002US6472506 Polysaccharide-peptide-conjugates
10/29/2002US6472502 Absorbable copolylactides and their use
10/29/2002US6472439 Orally administerable medicinal plant dry extracts, wherein the non-volatile phase of the extract is bound in a microdisperse form and/or in the form of a semisolid or solid solution to a first carrier which is soluble in or miscible
10/29/2002US6472431 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
10/29/2002US6472379 Angiogenesis inhibition
10/29/2002US6472368 Compounds and methods for modulating adhesion molecule function
10/29/2002US6472365 Pharmaceuticals and assays using enzyme subunits
10/29/2002US6472181 Hybrid matrix implants and explants
10/29/2002US6472178 Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
10/29/2002US6472176 Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
10/29/2002US6472146 Methods for identification on internalizing ligands and identification of known and putative ligands
10/29/2002US6471996 Lactone and lactide copolymer; copolymer of lactic acid, glycolic acid, and serine; drug delivery to immune systen
10/29/2002US6471992 Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
10/29/2002US6471991 Drug, water disintegratable, compressible carbohydrate, and a binder, tablet's face surfaces have a convex shape and tablet having given hardness and low friability; taste masking
10/29/2002US6471984 Cataplasm and tape-aid containing a plasticizer
10/29/2002US6471978 Localized use of nitric oxide-adducts to prevent internal tissue damage
10/29/2002US6471971 Ethanolic tinctures; preparations applied to the skin
10/29/2002US6471970 Use of pharmaceutical compositions capable of being gelled in periodontology
10/29/2002US6471968 Multifunctional nanodevice platform
10/29/2002US6471963 Pure pancreatic islet cell membrane antigen or epitope thereof that can bind to islet cell surface antibodies (icsa).
10/29/2002US6471955 Polystyrenes as preferential time-release agents or carriers of prostaglandins such as misoprostol used for prevention of peptic ulcers
10/29/2002US6471943 Formulation and method for treating neoplasms by inhalation
10/29/2002EP1144613A4 Methods for making proteins containing free cysteine residues
10/29/2002CA2263455C Liposomes containing a cisplatin compound
10/29/2002CA2221242C Viral agent associated with mystery swine disease
10/29/2002CA2115053C Antimicrobial dialdehyde composition and methods of use
10/29/2002CA2014486C Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyltrithio group
10/24/2002WO2002083945A2 Diagnosis and treatment of cancer: i
10/24/2002WO2002083928A2 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
10/24/2002WO2002083921A2 Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
10/24/2002WO2002083919A2 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
10/24/2002WO2002083917A2 Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
10/24/2002WO2002083916A2 Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer
10/24/2002WO2002083891A2 Nucleic acids for inhibiting hairless protein expression and methods of use thereof
10/24/2002WO2002083860A2 Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
10/24/2002WO2002083840A2 Compositions and methods for transepithelial transport of membrane-bounded vesicles and virions
10/24/2002WO2002083779A1 Improvements in or relating to modified cellulose films
10/24/2002WO2002083708A2 Selective covalent-binding compounds having therapeutic diagnostic and analytical applications
10/24/2002WO2002083689A1 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds
10/24/2002WO2002083687A1 3,7-diazybicyclo [3.3.1] formulations as antiarrhytmic compounds
10/24/2002WO2002083655A1 Prodrugs of cox-2 inhibitors
10/24/2002WO2002083632A1 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae
10/24/2002WO2002083626A2 Alkyl and/or alkenyl glycerol carbamates
10/24/2002WO2002083186A1 Nuclear receptor-mediated introduction of a pna into cell nuclei
10/24/2002WO2002083180A1 Elongated and multiple spacers in activatible prodrugs
10/24/2002WO2002083179A2 Fusion proteins
10/24/2002WO2002083178A1 Pharmaceutical composition based on macrolides for topical application in ophthalmology
10/24/2002WO2002083177A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002WO2002083176A2 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
10/24/2002WO2002083170A1 Vaccines including as an adjuvant type 1 ifn and processes related thereto
10/24/2002WO2002083166A1 Interferon-polymer complexes and medicinal use thereof
10/24/2002WO2002083165A1 Stable preparations for injection
10/24/2002WO2002083151A2 Compositions and methods for treating an arthritic condition
10/24/2002WO2002083150A1 Bisphosphonate conjugates and methods of making and using the same
10/24/2002WO2002083147A1 Use of bile acid or bile salt fatty acid conjugates
10/24/2002WO2002083121A1 Compositions for improving skin environment and clothes thereof
10/24/2002WO2002083117A1 Toluene sulfonamide-containing anti-tumor composition and method of use thereof
10/24/2002WO2002083113A2 Aerosol compositions containing formoterol and a steroid such as e.g. budesonide or fluticasone for delivery into the lungs via nebulization
10/24/2002WO2002083107A1 Adhesive emulsion for medical purposes made from ethylene-vinyl acetate copolymers and adhesive resins